amantadine has been researched along with fluoxetine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Balogh, S; Hendricks, SE; Kang, J | 1 |
| Brown, BS; Haertzen, CA; Hess, JM; Weddington, WW | 1 |
| Kanofsky, D; Lindenmayer, JP; Vakharia, M | 1 |
| Terao, T | 2 |
| Hendricks, SE; Miller, ME; Prendergast, MA; Yells, DP | 1 |
| Balon, R | 1 |
| Bancroft, J; Kim, Y; Michelson, D; Targum, S; Tepner, R | 1 |
| Sanders, TA; Taylor, D; Werneke, U | 1 |
| Balogh, SE; Hendricks, SE; Paige, SR; Prendergast, MA; Yells, DP | 1 |
2 review(s) available for amantadine and fluoxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; Metformin; Nizatidine; Obesity; Orlistat; Topiramate; Weight Gain | 2002 |
2 trial(s) available for amantadine and fluoxetine
| Article | Year |
|---|---|
Psychological reactions and retention by cocaine addicts during treatment according to HIV-serostatus: a matched-control study.
Topics: Adaptation, Psychological; Adult; Affect; AIDS Serodiagnosis; Amantadine; Baltimore; Cocaine; Combined Modality Therapy; Desipramine; Female; Fluoxetine; HIV Seropositivity; Humans; Male; Patient Dropouts; Psychotherapy; Sick Role; Substance-Related Disorders | 1991 |
Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention.
Topics: Adult; Amantadine; Anxiety Disorders; Buspirone; Depressive Disorder; Dopamine Agents; Female; Fluoxetine; Humans; Patient Selection; Placebos; Psychiatric Status Rating Scales; Research Design; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 2000 |
18 other study(ies) available for amantadine and fluoxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Treatment of fluoxetine-induced anorgasmia with amantadine.
Topics: Adult; Amantadine; Depressive Disorder; Fluoxetine; Humans; Male; Orgasm; Sexual Dysfunctions, Psychological | 1992 |
Fluoxetine in chronic schizophrenia.
Topics: Amantadine; Chronic Disease; Drug Therapy, Combination; Fluoxetine; Humans; Loxapine; Male; Middle Aged; Schizophrenia; Schizophrenic Psychology; Thiothixene | 1990 |
Titration of serotonin reuptake blockers.
Topics: Amantadine; Drug Administration Schedule; Fluoxetine; Humans; Mental Disorders; Recurrence; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Yohimbine | 1993 |
Monoaminergic influences on temporal patterning of sexual behavior in male rats.
Topics: Amantadine; Animals; Biogenic Monoamines; Catecholamines; Copulation; Dopamine Agents; Ejaculation; Female; Fluoxetine; Male; Ovariectomy; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior, Animal; Time Factors | 1995 |
Intermittent amantadine for fluoxetine-induced anorgasmia.
Topics: Adult; Amantadine; Dopamine Agents; Female; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological | 1996 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Meta-Analysis as Topic; Paroxetine; Personality Inventory; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome | 2001 |
Fluoxetine differentially suppresses sucrose solution consumption in free-fed and food-deprived rats--reversal by amantadine.
Topics: Amantadine; Animals; Dopamine Agents; Dose-Response Relationship, Drug; Drinking Behavior; Fluoxetine; Food Deprivation; Male; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sucrose | 2002 |